Fig. 1: A comprehensive immunological landscape is uncovered by longitudinal CyTOF data obtained from patients treated with mogamulizumab.

a Schematic overview of the CyTOF analyses. PBMCs (n = 4) obtained from pre- and post-mogamulizumab treatment were subjected to CyTOF. b UMAP projection of cells from pre- and post-mogamulizumab treatment samples is colored according to their scaled expression levels of markers for different cell populations: CD4⁺ T cells, CD8⁺ T cells, FoxP3⁺ T cells, CD20 for B cells, CD11c for monocytes. c The UMAP projection is colored according to the scaled expression levels of CCR4. The panels on the right represent the enlarged CD4⁺ cell populations to clearly show the changes in the expression levels of CCR4 pre- and post-mogamulizumab treatment samples. Black arrowheads represent Treg cells and CD8⁺ T cells. Each dot represents a single cell. Colors were saturated at z-cores 1 and 0 for visualization. d The UMAP projection is colored according to the cluster assignment by CYBERTRACK2.0. e. Heatmap generated by CYBERTRACK2.0. The rows and columns represent markers and clusters, respectively. Black arrowheads represent Treg cells and CD8⁺ T cells as in (c). f Boxplots representing the proportions of CD4⁺ clusters (clusters 8, p = 0.052; 9, p = 0.23; 10, *p = 0.049; 16, p = 0.12; 21, p = 0.41 and 22, p = 0.46) at pre- and post-mogamulizumab treatment (n = 4). g Boxplot representing the proportions of cluster 12 (p = 0.23), which contains CD8⁺ T cell populations at pre- and post-mogamulizumab treatment (n = 4). The center line indicates the median, and the box limits indicate the 1st and 3rd quartiles. Whiskers extend to the 1.5x interquartile range. In (f) and (g), two-sided paired Student’s t-test was used. *p < 0.05. Source data are provided as a Source Data file.